OmniActive Health Technologies Limited

Based in India, OmniActive Health Technologies specializes in creating innovative natural health supplements, particularly focusing on botanical extracts and specialty actives to enhance health and wellness. Founded in 2005 and headquartered in Mumbai, India, OmniActive Health Technologies develops high-quality natural health supplements. The company has secured four funding deals to date, with the most recent being a Secondary Buyout of INR 12,800 mn on August 23, 2023, led by TA Associates. OmniActive Health Technologies specializes in developing high-quality natural health supplements, focusing primarily on innovative botanical extracts and specialty actives.

Their core product offerings include Lutemax 2020, an award-winning extract derived from marigold flowers that combines lutein and zeaxanthin isomers, promoting eye health and cognitive performance. Other notable products include enXtra, a caffeine-free ingredient that supports energy and alertness, and Curcuwin Ultra+, a highly bioavailable curcumin designed for joint comfort and mobility. These products are targeted towards health and wellness brands, sports nutrition enthusiasts, and consumers seeking natural solutions for improved health. OmniActive serves a diverse client base that includes manufacturers and retailers in North America, Europe, and Asia, ensuring a broad geographical reach for their offerings.

In 2023, OmniActive Health Technologies reported revenue of INR 86,391,839. 20 and an EBITDA of INR 26,821,142. 40. The company generates revenue primarily through B2B transactions, supplying their specialized ingredients to health and wellness brands, manufacturers, and retailers.

The company operates on a partnership model, establishing collaborations with various brands to develop customized wellness solutions that meet specific market needs. Clients typically procure products based on their unique formulations, with transactions structured around bulk orders of specialty actives and botanical extracts, such as the flagship Lutemax 2020 and other proprietary ingredients. Pricing structures are tailored to individual client requirements and often reflect the premium quality and unique benefits of the products offered. This approach allows OmniActive to foster long-term relationships with clients, enhancing brand loyalty and market presence within the health and wellness sector.

In August 2023, AXIS Capital and Investec Capital provided INR 3. 7 billion in debt financing to support the refinancing of OmniActive Health Technologies Limited. The company aims to introduce new products targeting specific health benefits, with plans for expansion into European and North American markets by the end of 2024.